Wall Street brokerages forecast that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will report ($0.64) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Tetraphase Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.60). Tetraphase Pharmaceuticals reported earnings of ($0.61) per share in the same quarter last year, which indicates a negative year over year growth rate of 4.9%. The firm is expected to report its next earnings results on Wednesday, March 14th.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($2.88) per share for the current fiscal year, with EPS estimates ranging from ($2.95) to ($2.80). For the next financial year, analysts expect that the company will post earnings of ($2.20) per share, with EPS estimates ranging from ($2.63) to ($1.75). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting analysts’ consensus estimates of ($0.63). Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The business had revenue of $4.10 million for the quarter, compared to analyst estimates of $1.59 million. During the same period last year, the business posted ($0.58) earnings per share. The firm’s quarterly revenue was up 355.6% on a year-over-year basis.

A number of brokerages recently commented on TTPH. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. HC Wainwright raised their price objective on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, November 6th. Finally, BMO Capital Markets raised their price objective on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. Tetraphase Pharmaceuticals has an average rating of “Hold” and a consensus target price of $15.15.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down $0.25 during trading hours on Tuesday, hitting $6.26. 345,646 shares of the company were exchanged, compared to its average volume of 447,730. Tetraphase Pharmaceuticals has a fifty-two week low of $3.57 and a fifty-two week high of $9.93. The firm has a market capitalization of $321.86, a price-to-earnings ratio of -2.18 and a beta of 2.51.

In other Tetraphase Pharmaceuticals news, Director L Patrick Gage bought 3,880 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now owns 38,880 shares in the company, valued at $250,776. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jacques Dumas sold 7,167 shares of the firm’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total transaction of $44,507.07. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board grew its position in Tetraphase Pharmaceuticals by 54.4% in the third quarter. Canada Pension Plan Investment Board now owns 2,554,100 shares of the biopharmaceutical company’s stock valued at $17,470,000 after purchasing an additional 900,000 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Tetraphase Pharmaceuticals by 32.7% in the third quarter. Dimensional Fund Advisors LP now owns 1,461,807 shares of the biopharmaceutical company’s stock valued at $9,998,000 after purchasing an additional 360,552 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Tetraphase Pharmaceuticals in the third quarter valued at $7,915,000. Northern Trust Corp grew its position in Tetraphase Pharmaceuticals by 4.8% in the second quarter. Northern Trust Corp now owns 886,765 shares of the biopharmaceutical company’s stock valued at $6,323,000 after purchasing an additional 40,668 shares in the last quarter. Finally, Numeric Investors LLC grew its position in Tetraphase Pharmaceuticals by 1,363.3% in the second quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock valued at $5,379,000 after purchasing an additional 702,812 shares in the last quarter. 58.15% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/16/0-64-earnings-per-share-expected-for-tetraphase-pharmaceuticals-inc-ttph-this-quarter.html.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.